InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-16.0%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by MELTZER LESLIE, Chief Research and Development. Insider active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 3 disclosures have been logged. Activity tracked since 26 August 2025. The latest transaction was filed on 26 August 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations3 total
107,024 sharesCommon StockSEC:0001193125-26-224620:0
107,024 sharesCommon StockSEC:0001193125-26-224620
61,804 shares0Common StockSEC:0001127602-25-021056:0
3 of 3 declarations
About MELTZER LESLIE
Leslie Meltzer is the Chief Research and Development Officer at Apellis Pharmaceuticals, Inc. In this role, she oversees the company's research and development initiatives, focusing on innovative therapies to treat serious diseases. Ms. Meltzer plays a key role in guiding research projects and collaborating with scientific teams to ensure the success of product developments.
